TrialFrontiers in immunology2024

A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.

Steven P Treon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.